Contract research organisation (CRO) MMS Holdings (MMS) has partnered with Thread for its decentralised clinical trial platform (DCT) and DCT-enabled services.

Thread’s DCT technology enables quicker clinical trials and also provides improved access for research participants.

With this collaboration, MMS will become a full-service DCT provider, from electronic data capture (EDC) through the DCT completion.

MMS founder and CSO Dr Uma Sharma said: “Our partnership with Thread allows us to provide the highest level of service to our clients.

“Now, sites have more options and can use their preferred EDC platform to realise the full benefits of our DCT services.”

For clinical research sponsors looking for an easily accessible DCT offering, Thread offers a flexible approach.

Thread is also enabling clinical trials to be patient-centric and inclusive through its singular and fully configurable platform.

Before the commencement of trial execution steps and comprehensive data, writing and transparency services, MMS provides design, regulatory strategy and obtaining regulatory buy-in on the study. 

With the Thread technology and supporting services, sponsors and CROs will be able to manage hybrid and fully DCTs with the ability to capture subject and sites data remotely through digital recruitment, telehealth, eCOA, sensors and other solutions that are available. 

Thread CEO John Reites said: “Thread’s patient-centric platform and supportive consulting services provide a modern, decentralised research experience as a part of MMS’ overall offering to sponsors, sites and participants.”

Last month, Thread acquired US-based CureClick to improve the pathway from clinical trial awareness to access. CureClick provides the world’s first crowdsourcing platform built to accelerate clinical research awareness and participation.